CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02193880
NCT02193880N/ACompleted
CompareCT.gov

Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)

Ayman Saad·interventional·Posted Jul 18, 2014·Updated Apr 25, 2019

In Brief

A clinical study evaluating Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide. for Hematologic Neoplasms and Graft-Versus-Host Disease. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of post-transplant cyclophosphamide and a post-transplant infusion of donor cells, that have been specially processed to remove alpha beta t-cells, in patients undergoing a haploidentical allogeneic stem cell transplant to help reduce the risk of relapse without increasing the risk of graft-versus-host disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Neoplasms, Graft-Versus-Host Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 18, 2014
Enrollment StartOct 9, 2014
Primary CompletionMar 13, 2018
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 12.0 years ago

Interventions

Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.device

Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.